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Abstract 
Objective:  To determine the pharmacokinetic properties of oral pergolide in normal mares. 
Animals:  6 horses, 3-17 years of age, 355-582 kg 
Procedures:  In a randomized, cross over design six healthy adult female horses received 
pergolide (PO) 0.01mg/kg or placebo after 8 hours of fasting.  Samples were taken over a period 
of 6 day for each portion of the study (treatment or placebo) with a two week minimum wash out 
period between study periods.  Quantification of pergolide concentration was determined by 
UPLC-MS.  Quantification of α-MSH was determined by radioimmunoassay validated for 
horses.  Quantification of ACTH concentration was determined by chemiluminescent enzyme 
immunoassay. 
Results:  Pergolide was detected in all treated horses.  The relatively short time to peak 
concentration (0.5 hours) indicates a rapid absorption.  Mean maximum concentration measured 
was 4.05 ng/ml + 2.02 with a median time to maximum concentration being 0.415 hours 
(range:0.33-1.0).  The mean half life of pergolide was determined to be 5.86 hours + 3.42.  
Lower limits of quantitation for the UPLC-MS assay was 0.5 ng/ml.  α-MSH results were 
evaluated using a multiple analysis of variance assay for repeated measures comparing treatment, 
time, and period.  There was a significant treatment to period effect with p=0.02.  The effect of 
period appears to be more significant (p=0.06) compared to the effect of treatment (p=0.77).  No 
effect from pergolide was noted on ACTH concentrations. 
Conclusions and Clinical Relevance:  Horses appear to absorb and eliminate pergolide more 
rapidly than previously expected.  Based on this pharmacokinetic data the dosing strategies of 
pergolide may need to be altered.  However, assay sensitivity does need to be improved prior to 
recommendations being made. 
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CHAPTER 1 - Literature Review 
Over the last several decades, the number of geriatric horses presented to referral 
institutions has increased dramatically.7,36  This is likely a reflection of an increase in the number 
of older horses in the general population (estimate to be 7 to 20% of the horse population), and 
differences in attitudes in horse owners about viewing their horse as companion animals.7,36   
Pituitary pars intermedia dysfunction (PPID) or equine Cushing’s disease is probably the 
most common disease of older horses.38 There are at least 20 peer reviewed reports of PPID in 
horses published in the veterinary literature over the last decade.  Clinical signs of PPID vary in 
severity and include hirsutism, hyperhidrosis, polyuria, polydipsia, loss of muscle tone, and 
abnormal fat distribution.38 Progression of the disease can result in laminitis and/or 
immunosuppression that may require euthanasia. Horses with PPID have hypertrophy and 
hyperplasia of the pars intermedia which leads to over expression of proopiomelanocortin 
(POMC).35,38  There are several diagnostic tests for documenting PPID in horses.12,13,38 The most 
common include endogenous ACTH concentrations and an overnight dexamethasone 
suppression test.12,13  The treatment of choice for PPID is pergolide, a dopamine agonsits.  
Pergolide was initially used in human medicine to treat Parkinson’s disease and restless leg 
syndrome; however it has been pulled from the market due to cardiac complications.  Pergolide 
has been used in horses for years to treat PPID; however there are no reports of it 
pharmacokinetic or pharmacodynamic properties.  Treatment regimes of horses with PPID have 
typically been based on human literature and response to therapy. 
 
Pituitary Gland 
Anatomy 
The pituitary gland, also called the hypophysis, is a small gland located ventral to the 
optic chiasm that connects to the hypothalamus via the pituitary stalk.16  Embryological 
development of the pituitary gland is from both neural and epithelial substrates.23  Based on the 
embryologic tissue, the pituitary gland is divided into the neurohypophysis (neural tissue) and 
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the adenohypophysis (epithelial tissue).23    The neurohypophysis is further divided into the pars 
nervosa and pars eminens.23  The adenohypophysis is further divided into the pars tuberalis, pars 
intermedia, and pars anterior or pars distalis (Figure 1.1).23,38 Use of the terms anterior or 
posterior are anatomically incorrect for quadripedal species, as the neurohypophysis usually lies 
dorsal to the remainder of the pituitary gland.  The neurohypophysis is actually embedded within 
the adenohypophysis in the horse.  The pars intermedia lies in a continuous rim located between 
the pars distalis and the pars nervosa.23  Vascular supply to the neurohypophysis and pars 
intermedia is through both the portal veins (ventral and dorsal) as well as direct arterial supply 
from systemic circulation.38  The pars distalis vascular supply is through the dorsal and ventral 
portal veins.23  
The neurohypohysis is made up of a collection of nerve axons and terminals that 
originate in the supraoptic and paraventricular nuclei of the hypothalamus.26  The cell bodies of 
these neurons produce oxytocin and arginine vasopressin (or anti-diuretic hormone ADH) which 
is stored in the pars nervosa for release into systemic circulation.26  The pars distalis is composed 
of a heterogeneous cell population with 5 different cell types.  These include somatotrophs, 
lactotrophs, corticotrophs, gonadotrophs, and thyrotrophs.38 The pars intermedia is composed of 
a single endocrine cell type, melanotrophs. 
Function 
The function of the adenohypophysis is to produce and store hormones necessary for 
daily physiologic functions.38  Somatotroph cells produce growth hormone while lactotrophs 
produce prolactin.38  Gonadotrophs produce hormones important for follicular growth and 
ovulation including follicle-stimulating hormone and luteinizing hormone.  Thyrotrophs produce 
thyrotropin.  These hormones are secreted based on either neural or hormonal stimulation from 
the hypothalamus.16  Most of the stimulation for the pars distalis comes from hypothalamic 
releasing factors delivered by the ventral and dorsal portal veins.23  The exact function of the 
pars tuberalis is currently unknown. 
Corticotrophs of the pars distalis and melanotrophs of the pars intermedia produce the 
same precursor protein pro-opiomelanocortin (POMC).  Due to different posttranslational 
processing each cell type secretes a different complement of POMC-derived peptides.   
Corticotrophs primarily produce adrendocorticotropin (ACTH), while melanotrophs produce α -
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melanocyte stimulating hormone (α-MSH), β-endorphin (β-END), corticotrophin-like 
intermediate peptide (CLIP), and only a very small amount of ACTH.  In corticotrophs of the 
pars distalis, prohormone convertase I is present which converts the majority of the POMC 
protein into ACTH, see Figure 1.2.26  In melanotrophs of the pars intermedia, prohormone 
convertase I and II are present.  The presence of both hormones results in cleavage of the POMC 
protein into α-MSH, β-END, CLIP, and a small amount of ACTH, see Figure 1.3.26  Further 
processing of the hormones produced is performed to regulate their activity and is affected by 
disease states, see Figure 1.4.26 
Melanotrophs of the pars intermedia are innervated by hypothalamic periventricular 
dompaminergic neurons.26  The release of the neurotransmitter dopamine from these neurons 
causes tonic inhibition of release of hormones from surrounding melanotrophs.26  After release 
dopamine binds to dopamine (D2) receptors on melanotrophs which inhibit the transcription of 
POMC and inhibit the release of POMC derived peptides.26  Dopamine also inhibits cell 
proliferation of the melanotrophs in the pars intermedia.  Melanotrophs are stimulated by the 
release of melanotrope releasing factor from the hypothalamus.26  Exogenous thyroid releasing 
hormone (TRH) is known to stimulate melanotrophs secretory activity, however the 
physiological significance of this is unknown at this time.   
The corticotrophs of pars distalis produce ACTH in response to pulsatile stimulation of 
corticotrophin releasing hormone (CRH) and arginine vasopressin released from the 
hypothalamus.38  Once released ACTH acts on the zona fasiculata of the adrenal cortex which 
causes the production and release of cortisol (glucocorticoid).  Inhibitory feedback on the release 
of ACTH occurs at the level of the hypothalamus and pars distalis in response to appropriate or 
high levels of adrenocortical steroids.23  This inhibition is primarily mediated through type II 
receptors located in the arginine vasopressin and CRH secreting neurons as well as the 
corticotrophs of the pars distalis.23  Although the pars intermedia does produce smaller amounts 
of ACTH, it does not experience the same inhibitory feedback as the pars distalis.21   
The physiologic effects of the POMC related peptides including α-MSH, β-END and 
CLIP are not well documented in the horse, but are better described in other species.26 α-MSH is 
primarily thought of as a hormone responsible for skin or coat pigmentation when it interacts 
with melanocortin receptor 1 which is found predominately on the skin.26  Interaction with 
melanocortin receptor 3 and 4, which are found in the central nervous system especially the 
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hypothalamus, are essential for the control of energy homeostasis.26  At this level their function 
is involved in the leptin-melanocortin pathway which regulates fat metabolism and appetite-
satiety balance.26  Obesity is found to affect humans and horses that lack these receptors.  α-
MSH has also been found to have profound anti-inflammatory effects with the regulation of the 
cytokine response by inhibiting the activation of nuclear factor-κB by lipopolysaccharide and 
interferon-γ.26  Recently McFarlane et al. in 2004 found that there is a significant rise in α-MSH 
in normal horses and ponies in the late summer and fall, which may correlate to decreasing 
daylight hours.28 It is thought that this rise helps to prepare the horses for winter time and 
decreased food provisions.  β-END has been found to provide analgesia (endogenous opiod), 
behavior modification, immune system modulation, and an effect on vascular tone.26  CLIP has 
been studied the least of the POMC peptides but it is thought that it may have an affect on insulin 
secretion.26   
The POMC peptide, ACTH is primarily produced by the pars distalis.  The primary 
physiological effects of ACTH include increased cortisol production.  The physiological effects 
of cortisol are widespread, and include changes in metabolism of glucose, protein and fat.  
Cortisol stimulates gluconeogenesis through mobilization of extrahepatic amino acids and 
through the production of amino acids from carbohydrates in the liver.16  Cortisol also results in 
decreased glucose utilization by peripheral cells, which may be in part due to a decrease in 
insulin sensitivity. Glucocorticoids increases lipolysis for the production of fatty acids and 
further production of glucose.16  Cortisol also possesses several anti-inflammatory properties, 
which are also considered immunosuppressive.  These effects are caused by multiple 
mechanisms which include the stabilization of lysosomal membranes, decreasing the migration 
of white blood cells into inflamed area, decreasing phagocytosis of damaged cells by white blood 
cells, decreasing permeability of capillaries, reducing the release and possibly binding of 
interleukin-1 from white blood cells, and decreasing T lymphocyte production or survival.16   
 
Pituitary Pars Intermedia Dysfunction (PPID) 
Pathophysiology 
Although PPID has occurred in the geriatric horse population since first being recognized 
in 1932, the exact pathophysiology of the disease was not elucidated until the last 25 years.38  It 
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was not until Millington et al. in 1988 found that affected horses had a decrease in dopamine 
concentrations in pituitary tissues that lead to the true understanding of the pathophysiology of 
this disease.34 In this study Millington found that horses affected with PPID had an 88% 
reduction in dopamine concentrations compared to age matched controls.34  Following this study 
McFarlane et al. in 2005 utilized immunohistochemistry to find that PPID affected horses had a 
50% reduction in the number of periventricular cell bodies compared to age matched control 
horses.25,29  The data from these studies strongly support the theory that PPID is due to a 
dopaminergic neurodegeneration. It is noteworthy that PPID is a misnomer given that this 
syndrome is primarily a hypothalamic disease, and not a primary pituitary disease 
Dopaminergic neurodegeneration in PPID is very similar to the pathology that occurs in 
Parkinson’s disease, although there are significant differences.  The primary clinical signs of 
Parkinson’s disease are progressive motor dysfunction, while the primary clinical signs of PPID 
are due to hormonal dysfunction.  The disparity of clinical signs is likely due to differences of 
the location of the dopaminergic neurodegeneration within the central nervous system.  The 
motor dysfunction in Parkinson’s disease is due to loss of nigrostriatal neurons, while the 
hormonal dysfunction in PPID is a result of loss of periventricular hypothalamic neurons.25  The 
exact cause of the dopaminergic neurodegeneration is still being evaluated; however there is 
recent evidence that oxidative stress likely plays a role with both diseases.   Reactive oxygen 
species produced during transmitter metabolism by the dopaminergic neurons are capable of 
damaging these neurons since they are exquisitely sensitive to their effect. 29    McFarlane et al. 
2005 documented that aging alone results in an increase in oxidative stress.  Aged horses have an 
increase amount of 3-nitrotyrosine and α-synuclein within the par intermedia when compared to 
younger horses.29 However, PPID horses had significantly higher amounts of 3-nitrotyrosine and 
α-synuclein even when compared to aged matched controls. The cause of the oxidative stress in 
normal geriatric horses and PPID horses is not a result of a reduction in systemic antioxidant 
capacity.31  However, this particular study suggested that there may be a decrease in the local 
antioxidant capacity within the pars intermedia of affected horses. 
Dopamine, as discussed previously, is released from the hypothalamic periventricular 
neurons.  It inhibits growth of the cells of the pars intermedia and decreases production of 
POMC peptide related hormones.  With the loss of dopamine, the cells of the pars intermedia are 
allowed to become hypertrophic and hyperplastic.  This proliferation of the pars intermedia cells 
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allows can result in macroadenomas (>1cm in diameter) or microadenoma formation.  Post-
mortem examination will often reveal a grossly enlarged pituitary gland.  When evaluating PPID 
affected horses Heinrichs et al. found that out of 19 horses, 13 horses had pars intermedia 
macroadenomas while only 6 had pars intermedia microadenomas.17  A majority of the 
macroadenomas observed replaced the pars distalis in affected horses. This finding was also 
appreciated by van der Kolk in 1996, when he evaluated 24 PPID affected horses that had 
pituitary glands that weight two to three times more than normal pituitary glands43.   The pars 
intermedia tumors typically have a low mitotic index and do not metastasize.38  The tumors are 
also well vascularized and commonly have associated hemorrhages; however they do typically 
lack a distinct capsule.38  Other tumors including pars distalis and a functional adrenocortical 
neoplasm have been associated with PPID like syndrome, however they are rare and do not have 
the same pathophysiology as tumors of the pars intermedia.6,45   
The loss of the inhibitory control of dopamine not only allows the cells of the pars 
intermedia to proliferate. These cells also produce and release increased levels of the POMC 
protein derivatives.38  It is important to note that in other species serotonin plays a major role in 
production of POMC peptides, however the importance of serotonin in the pars intermedia of 
horses remains unclear.41  Immunostaining of affected pars intermedia has revealed an increase 
in the amount of α-MSH, β-MSH, γ-MSH, β-END, CLIP, and to a lesser extent ACTH.  
Normally the production and secretion of ACTH is under inhibitory feedback in the pars distalis. 
The pars intermedia does not respond to this inhibitory feedback, however production of ACTH 
in the pars distalis does diminish considerably.21,38,42    Although the majority of clinical signs 
associated with PPID are considered to be due to an increase in ACTH production, 
immunostaining has not provided support for this theory.  Instead, it has been found that the 
MSH-related peptides and β-END, which increase dramatically, greatly potentiate the 
adrenosteriodogenic effects of ACTH.21   
 
Clinical Signs 
PPID is most commonly seen in horses over the age of 15 years, so it is considered a 
disease of the increasing geriatric population of horses.  Overall, the incidence of PPID does not 
appear to be rising but our population of geriatric horses has increased as has our recognition of 
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the disease.  PPID affects all genders.  PPID affects all breeds, but in some studies ponies and 
Morgans were overrepresented.25  There is evidence that ponies have a longer lifespan than 
horses. A table of number of horses, ages, and gender in 6 studies of PPID are listed in Table 1.1.  
Common clinical signs vary widely, but the most common clinical sign appreciated is hirsutism.  
Common clinical signs and their incidence in 6 studies are listed in Table 1.2. 
Hirsutism is a unique clinical sign with horses with PPID and is described as an 
abnormally long curly coat that fails to shed.  More subtle hair coat abnormalities will often 
develop before hirsutism.  These changes include small areas of long hairs amongst a normal 
coat or a winter coat that comes in early and reluctant to leave the following spring.24,41  This 
mild abnormality may then proceed to a full thick coat of curly hair that does not shed normally.  
The coat may change to a lighter color in darker horses.38,42  The exact mechanism for the 
development of hirsutism in horses affected by PPID is not understood, however the current 
hypothesis is that it is due to chronic elevations of MSH peptides.38  Another clinical sign of 
PPID that is not well understood is hyperhidrosis.  A physical pressure caused by the enlarged 
pars intermedia on the thermoregulatory center of the hypothalamus, a direct effect of increased 
β‐endorphin, or simply an inability to dissipate heat normally due to the long hair coat are 
possible proposed theories for the develop hyperhidrosis.24,38   
Polyuria and polydipsia (PU/PD) has also been reported in at least one third of horses 
affected with PPID.38  The hypothesized mechanism of the cause of PU/PD in PPID horses 
varies greatly.  Hypotheses primarily consider the overproduction of ACTH and cortisol the main 
causes, however this does not always appear to be the case.  Hypothesis for PU/PD include: 1) 
hyperglycemia and glucosuria resulting in osmotic diuresis; 2) cortisol increases the glomerular 
filtration rate; 3) cortisol inhibits release and/or action of arginine vasopressin; 4) compression of 
the pars nervosa resulting in a decrease in arginine vasopressin, and 5) cortisol and ACTH 
inhibiting the renin-angiotensin-aldosterone axis.24,26,38,41   It has also been hypothesized that due 
to the immunosuppression activity of cortisol, a urinary tract infection may be present and cause 
PU/PD.24,38  PU/PD has also been associated with hyperhidrosis that commonly occurs in PPID 
affected horses.  The true frequency of osmotic diuresis resulting in PU/PD is unknown, as 
glucosuria in horses with PPID and PU/PD was an uncommon finding in one report.38  
Abnormal fat distribution is commonly seen in horses with PPID.  Common areas of fat 
deposition in PPID horses include the tailbase, supraorbital fossa, crest of the neck and 
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sheath.26,38 The proposed mechanism of this abnormal deposition of fat is due to 
hyperinsulinemia.  However, as mentioned earlier the combination of the other more commonly 
produced POMC peptides may potentiate more of the signs commonly associated with increased 
cortisol production. Abnormal fat deposition is typically followed later in the disease process by 
weight loss and muscle wasting.  Weight loss is most likely due to a combination of multiple 
problems including poor dentition, parasitism, chronic infections, reduced exercise, poor 
nutrition, and increased protein catabolism.26  Muscle wasting appreciated in these horses is 
considered to be due to increase cortisol production.  Muscle biopsies performed on affected 
horses reveal type 2 myofiber atrophy, which is consistent with corticosteroid muscle atrophy in 
other species.26  The muscles most commonly affected are those muscles associated with the 
rump and the epaxial musculature.26,38  With this type of muscle loss and abnormal fat 
distribution, horses commonly develop a very round abdomen.38   
Chronic infections or delayed wound healing is another common finding in PPID affected 
horses.  Common infections include parasitism, sinusitis, respiratory infections, skin infections, 
tooth root abscesses, pneumonia (broncho, pleuro, fungal), recurrent subsolar abscesses, and 
conjunctivitis.26,38,42  Many of these infections may initially respond to appropriate therapy and 
then either slow down recovery or have recurrent bouts of infection.  PPID horses that develop 
broncho or pleuropneumonia typically have a mixed population of causative agents and can also 
have fungal involvement.38,42  Affected horses that are not on appropriate parasitic prophylaxis 
can develop severe intestinal parasitism.26  Immunosuppression associated with PPID is 
commonly considered to be due to increased ACTH and thus cortisol production.  However, as 
mentioned previously the other POMC peptides help to potentiate the effects of cortisol.  Also, 
β-END itself has immunosuppressive effects, especially by decreasing T-cell blastogenosis.  To 
evaluate immune system status in PPID affected horses, McFarlane et al. in 2008 evaluated 
cytokine distribution in aged horses, age-matched horses affected with PPID, and adult (non-
geriatric) horses.30  In this study, normal aged horses had increased concentrations of 
inflammatory cytokines,(including interleukin-6, interleukin-8, and interferon-γ); indicating that 
aging is associated with a pro-inflammatory state.30  In contrast to the normal aged horses PPID 
affected horses had decreased levels of interleukin-6 and interferon-γ, but had very similar levels 
of interleukin-8.30   
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Chronic laminitis occurs in PPID affected horses and has the potential to be a life-
threatening complication.  Chronic laminitis is reported to occur in 20 to 84% of horses affected 
by PPID.11    Donaldson et al. in 2008 evaluated 40 horses with laminitis for evidence of PPID.  
In this study 70% of the horses appeared to be affected by PPID and horses appeared to be more 
likely to develop laminitis during September and May.11  The exact pathophysiology in the 
development of laminitis still remains poorly understood and appears to be multifactorial.  Most 
hypotheses revolve around the increase in ACTH/cortisol production or potentiation of its effects 
including hyperglycemia, insulin resistance, hyperinsulinemia, and the catabolic effect of 
cortisol.  One hypothesis is that the insulin resistance induced by glucocorticoids starves the 
sensitive laminae tissue of glucose, its energy substrate, resulting in laminae death.26  However, 
in a recent report GLUT-4 (an insulin dependent glucose receptor) was not detected in laminar 
tissue, and glucose uptake in lamellar tissues was independent of insulin.1  Another hypothesis is 
that based on the catabolic nature of cortisol that the integrity of the laminae is diminished, 
leading to recurrent bouts of laminitis.11    High concentrations of insulin may play a direct role 
in the development of laminitis.  An experimental model resulting in hyperinsulinemia (and 
normoglycemia) resulted in laminitis in normal ponies.2   
There are many other clinical signs associated with PPID, however these appear to be 
less common than the previously discussed clinical signs.  Lethargy or a behavior change to a 
more subdued horse is considered to be due to an increase in β-END.41  This increase in β-END 
has also been considered to be the reason that some PPID affected horses have a decreased 
response to pain.41  Neurologic signs including seizures, abnormal vision, blindness, ataxia, and 
narcolepsy have been reported and may be associated with compression from a 
macroadenoma.38,41  Infertility and persistent lactation has also been reported in PPID affected 
mares.38  The cause of persistent lactation is most likely due to the lack of dopaminergic 
inhibition of prolactin.  Possible causes of infertility in these mares could be due to destruction of 
gonadotrophs by the pars intermedia adenoma or suppression of gonadotropin secretion by 
glucocorticoids.24,38 Another source of infertility could be the decreased ability to clear uterine 
infections.  Despite reports of infertility in PPID affected horses there are reports of successful 
pregnancies and parturition occurring in PPID affected horses.38   
Another clinical sign more commonly seen in humans with hypercortisolism is 
osteoporosis.38,42  Specific reports of osteoporosis in horses with PPID are lacking. However 
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there are multiple incidences of PPID horses being euthanized after fractures or fractures during 
surgical recovery in PPID horses.38  The exact pathologic process is not completely understood.  
Hypertrophic osteopathy has been reported in a pony with a pituitary adenoma.38  Another 
musculoskeletal condition commonly associated with PPID is the breakdown of the suspensory 
apparatus especially hind limb, which can result in the necessity of euthanasia.        
There are several abnormal clinicopathologic findings associated with PPID.  Complete 
blood count (CBC) abnormalities reveal a stress leukogram consisting of a mature neutrophilia 
and an absolute lymphopenia.38  Eosinopenia and anemia have also been described.38,41  Serum 
chemistry abnormalities include hyperglycemia, hypertriglyceridemia/hyperlipemia, increase in 
liver enzymes, and hypercholesterolemia.  Glucosuria is reported in PPID affected horses in 
association with hyperglycemia.41  The majority of these abnormalities are hypothesized to occur 
due to increased levels of cortisol or the potentiated effect by the POMC peptides.  Horses are 
typically resistant to hepatic changes induced by glucocorticoids, however with insulin resistance 
and increased lipolysis by the glucocorticoids fat disposition in the liver may occur.38   Resting 
insulin concentrations are often increased, consistent with insulin resistance in horses with PPID. 
Diagnosis 
Multiple diagnostic tests exist for PPID, each with its own limitation.  As we have used 
these tests over the years and have learned more about the disease itself, it has become clear that 
no test is perfect and will correctly diagnose each case. Validation for any diagnostic test 
requires comparison to a known gold standard.  Postmortem histologic evaluation of the pars 
intermedia has been considered the gold standard for diagnosis of PPID.  However, there is lack 
of consensus in histologic interpretation of pituitary glands from aged horses with mild clinical 
signs of PPID.31 Histologic changes of the pars intermedia of healthy aged horses likely overlap 
with lesions observed in early disease.  Van der Kolk et al. in 2004 reported that pathological 
changes of the pituitary gland (cysts, hyperplasia, microadenomas, and macroadenomas) 
increases with age.44  Additionally,  this study also found that pregnancy and lactation resulted in 
an increase in pituitary weights.  Season (likely due to decreasing daylight hours) also adversely 
affects diagnostic tests for PPID.   POMC peptides concentrations (including ACTH and α-
MSH) start to increase in the late summer and fall in normal horses.  It is unknown if season 
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affects POMC peptide production in PPID horses.  It is very likely that season affects all 
diagnostic tests for PPID.   
There are numerous diagnostic tests that have been performed and evaluated over the 
years for PPID.  Ante-mortem diagnostic tests include baseline plasma cortisol or loss of diurnal 
rhythm, dexamethasone suppression test, ACTH stimulation test, TRH stimulation test, 
combined TRH dexamethasone suppression test, baseline POMC peptide concentrations, serum 
insulin concentration, urinary corticoid-to-creatinine ratio, salivary cortisol concentration, 
domperidone ACTH stimulation test, and diagnostic imaging (radiographs, computed 
tomography, and magnetic resonance imaging).38  Although each of these diagnostic tests has 
their own advantages and disadvantages it appears that none are without fault.  Baseline plasma 
cortisol or loss of diurnal rhythm, dexamethasone suppression test, ACTH stimulation test, TRH 
stimulation test, combined TRH dexamethasone suppression test, endogenous POMC peptides, 
and domperidone ACTH stimulation test will be discussed individually as they have shown to be 
the diagnostic tests most commonly used and shown most promise in eliminating errors in 
testing. 
 
Resting or Baseline Plasma Cortisol Concentration 
This diagnostic test measures baseline cortisol in a horse without stimulation by ACTH 
or inhibitory feedback with glucocorticoids.  This test is very difficult to interpret due to multiple 
causes such as that affected horses typically have baseline cortisol within reference range 
approximately 47% of the time.42  There is also the concern of the cortisol level being altered by 
stress or exercise prior to sample collection.  Horses have been documented to have a diurnal 
rhythm with the most significant rise in cortisol in the morning; this can also affect test results 
depending on the time of sample collection.14,38  A suggested variation of this diagnostic test is 
the evaluation for a loss of the normal diurnal rhythm of the horse; this is considered to be less 
than 30% variance from the morning to evening sample of plasma cortisol.38  This test has not 
been substantially validated in horses to be considered useful in the diagnosis of PPID, unless the 
use of glucocorticoids is prohibited.38 
Dexamethasone Suppression Test 
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This test has been considered the “gold standard” of the endocrine tests by many 
practitioners and researchers.  There are several variations of the dexamethasone suppression 
test, including an overnight and 24 hour suppression test.  The 24 hour dexamethasone 
suppression tests requires multiple samples, at inconvenient times, which makes this test less 
preferred than the overnight dexamethasone suppression test.  Dexamethasone suppression tests 
rely on negative inhibitory feedback caused by dexamethasone on ACTH and cortisol secretion.  
Since the pars intermedia does produce ACTH but does not respond to the negative feedback of 
increased glucocorticoid, horses affected with PPID should not have suppressed cortisol 
concentrations after dexamethasone administration.24,26  Studies have shown that PPID affected 
horses do initially have cortisol suppression following dexamethasone, but that they break out of 
that suppression much sooner than normal horses.24,41  A dexamethasone suppression test is not 
without risk in PPID affected horses, especially those that have had laminitis.  The 
administration of dexamethasone has the potential to exacerbate laminitic episodes in these 
horses.11,38  
The overnight dexamethasone suppression test requires collection of blood during one to 
three time points, which varies among reports.26,41   Blood is usually collected (for measurement 
of cortisol concentrations) immediately prior to administration of dexamethasone; however 
collection of this blood sample is not necessary.  A dose of 40µg/kg body weight of 
dexamethasone is given intramuscularly at 5:00pm.  Blood samples to evaluate for suppression 
of cortisol can be performed at 15 hours, however generally 19 hours post dexamethasone 
administration is considered to be adequate.26,41  Suppression is considered to have occurred 
when circulating cortisol is less than 1 µg/dl at the 19 hour sample.  A diagnosis of PPID can be 
made is cortisol concentrations are greater than 1 ug/dl 19 hours dexamethasone administration.   
The overnight dexamethasone suppression test was first reported by Dybdal et al. 1994, 
with 100% sensitivity and specificity when blood samples were collected 19 hours after 
dexamethasone administration.13  However, upon further clinical evaluation, the sensitivity and 
specificity of this test is probably much lower.  There are several reasons that might explain the 
disparity between the initial report, and this observation.   Sensitivity is likely affected by 
severity of the disease.  Horses with mild PPID will likely have more cortisol suppression than 
horses with advanced disease.  Season affects dexamethasone suppression tests results in normal 
horses, and false positive tests are more likely in the fall.  Donaldson et al. in 2005 found that 
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cortisol concentrations were highest in September after performing an overnight dexamethasone 
suppression test.12    
Adrenocorticotropin Stimulation Test 
As previously mentioned the increase in circulating cortisol in PPID affected horses is 
due to pars intermedia adenoma formation; however in most humans and canines excess cortisol 
is due to an overactive adrenal cortex.  Adrenal gland hyperplasia is reported in approximately 
20% of PPID horses.38 This test provides exogenous adrenocorticotropin (ACTH) and then 
evaluates cortisol levels as a response.  This test is performed by administering ACTH 
intramuscularly (1 IU/kg ACTH gel) or intravenously (25 IU ACTH1-24 or 100 IU of synthetic 
ACTH) then collecting blood samples to evaluate cortisol response.  The intravenous testing 
method appears to be more beneficial with statistical significance identified between normal and 
PPID horses.41  This test is thought to be more beneficial in testing for adrenal gland function, 
especially when considering exhaustion.  However, this test failed to discriminate between 
horses with PPID and normal horses, and is not recommended for testing for PPID.41 
Thyrotropin-Releasing Hormone Stimulation Test 
The thyrotropin-releasing hormone (TRH) stimulation test has been used for a number of 
years to evaluate horses with PPID.  This test was first evaluated by Beech and Garcia where 
they administered 1mg TRH IV to healthy and PPID affected horses, then evaluated plasma 
cortisol concentrations.4,41 They found that thyroid hormones rose in all horses, as expected, 
however the cortisol levels in PPID horses rose significantly compared to control horses. In 
addition to evaluating TRH’s effect on cortisol, Beech et al. in 2007 evaluated the effect of TRH 
on ACTH concentrations and compared it to the overnight dexamethasone suppression test in 
PPID and normal horses.3  In this study there was an increase in ACTH concentrations associated 
with TRH administration in all horses, with a significant increase in horses with PPID.  It was 
determined from this study that the TRH stimulation test had a high sensitivity (86-100%) and 
specificity (24-88%), although the specificity was less than the overnight dexamethasone 
suppression test.3   
 The exact mechanism of how TRH causes an increase in cortisol has not been known 
until recently.  McFarlane et al. in 2006 evaluated α-MSH concentrations in response to TRH 
administration.  They found that plasma α-MSH concentrations increased by 600% in response 
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to TRH administration in all horses (normal and PPID horses).26,27  This response indicates that 
TRH stimulates the melanotrophs of the pars intermedia, which would then lead to increased 
levels of ACTH and cortisol.26,27 
The TRH stimulation test is performed by administering 1mg of TRH intravenously.  
Blood should be collected prior to administration; however there are multiple collection times 
listed in the literature but mainly include 15, 30, and 90 minutes post TRH administration.38  The 
test is typically considered positive if plasma cortisol concentrations show a 30% increase 
between 15 and 90 minutes post-administration.38  The main advantage of this test is that it does 
not involve the administration of dexamethasone which could result in laminitis in some PPID 
horses.  Another advantage of this test is the short testing time period.  Disadvantages of this test 
include the multiple sampling times and in the past TRH have been difficult to obtain.  The 
improved availability of compounded TRH has decreased cost and difficulty in performing the 
test.  Another concern about this test is the lack of an established sensitivity and specificity.26 
Combined Dexamethasone Suppression Test/Thyrotropin Releasing Hormone Stimulation 
Test 
The combined dexamethasone suppression test TRH stimulation test was developed to 
decrease the influence of a variable initial cortisol concentration when using the TRH test 
alone.38  This test is considered to be more sensitive since it does utilize two useful diagnostic 
tests in series.  The conceptual explanation of this test is that by administering dexamethasone, 
cortisol concentration decreases.  With the reduction in the baseline cortisol concentration, it is 
easier to discern the horse’s response to TRH.  The test is performed by administering 40µg/kg 
dexamethasone intravenously 3 hours prior to the administration of TRH (1 mg 
intravenously).38,41  Circulating cortisol levels are measured prior to TRH administration, then at 
15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes, and 21 hours after TRH 
administration.41   
This test was critically evaluated by Frank et al. in 2006, and test results were compared 
to the gold standard (histology).15  The combined test had a sensitivity of 88%, a specificity of 
76%, a positive predictive value of 71%, and a negative predictive value of 90%, for the 
population studied (prevalence of PPID = 40%).15 In this study the results of the combination test 
was compared to the overnight dexamethasone suppression test alone, the TRH stimulation test 
alone, and histopathology.15  Based on their findings, it was determined that this test was more 
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sensitive than either component alone; however it was not as specific as the TRH stimulation test 
alone.15  Despite the advantage of improving the sensitivity of testing, this test is not used widely 
due to the amount of time required for administration and multiple blood samples that are 
required.  Also, there is an increased cost to administer this test (time, samples, and drugs) and 
still increased risk for laminitis with the administration of dexamethasone. 
Endogenous POMC peptides 
The measurement of POMC peptides is considered to the easiest, safest, and most cost 
effective test to diagnose PPID.  ACTH is the most common peptide tested for and is available 
commercially.  α-MSH and β-END have also been reported to be elevated in PPID horses.  The 
sensitivity of measuring baseline ACTH has been reported to be 80% while the specificity has 
reported to be 90%.26  This estimate is likely over estimated since it is compared to the overnight 
dexamethasone suppression test as the gold standard.   
Measuring ACTH concentration is used commonly because it eliminates multiple sample 
times as well as eliminating the administration of dexamethasone, thus providing a safer test for 
laminitis prone horses.  It is important to note that even though ACTH concentrations may be 
elevated, circulating cortisol may be within normal limits.  It is also important to remember that, 
as Donaldson et al. found, ACTH levels are significantly increased in September compared to 
January or May in even normal horses.12  Testing at an inappropriate time of year could lead to 
false positives.  A disadvantage of measuring ACTH concentrations is that it is a sensitive 
peptide that can be damaged by handling mistakes.  In contrast α-MSH is less sensitive to 
handling mistakes and has been shown to be a possible diagnostic tool for PPID, although it is 
also affected by season.   
Domperidone ACTH Stimulation Test 
The domperidone ACTH stimulation test is a very recent test reported by Miller et al. in 
2008.33  The conceptual theory of this test is that since PPID results in pars intermedia 
hyperplasia, administration of domperidone (a dopamine antagonist) will result in an increase 
release of ACTH in PPID horses.  Miller et al. evaluated not only the horses ACTH 
concentration but also pituitary histopathology assigning a grading system.33  The test was 
performed by measuring plasma ACTH, then administering 3.3mg/kg domperidone orally.  
ACTH concentrations were measured 4 and 8 hours after domperidone administration.   
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Miller et al. assigned grades 1 through 5, with 1 being normal and 5 being a 
macroadenoma.33  In this study they found that horses with histologic grades greater than or 
equal to 3 consistently had greater levels of circulating ACTH concentrations in response to 
domperidone administration.33  Benefits of this test include that it is more sensitive than resting 
endogenous ACTH concentrations and that it does not involve the possible risk of laminitis 
associated with dexamethasone administration.  Disadvantages of this test include multiple 
testing times and the cost associated with domperidone .  The effect of season has not been 
critically evaluated with this test, however it would be assumed that as with other tests that 
measure ACTH it would be preferable to not test in the autumn of the year. 
 
Treatment 
Treatment of PPID in horses involves management changes as well as pharmacological 
therapy.  Management changes in these horses are necessary not only because of their disease 
status but also due to the increased age that PPID typically occurs in horses.  Pharmacological 
therapy for PPID horses has typically focused on replacing POMC inhibitory compounds, but 
has also included drugs that inhibit adrenal steroidogenesis. 
Management changes for horses affected with PPID include body clipping to help horses 
affected with hirsutism and hyperhidrosis.38  It is also imperative to provide adequate dental care 
to these horses to allow them to masticate normally and decrease the likelihood of tooth related 
problems that may be enhanced by the immunosuppressive nature of PPID.  A proper diet that 
not only provides adequate nutrition but is also easily masticated is also beneficial for these 
horses.  These horses should be monitored for weight loss and muscle loss over time, with 
appropriate adjustments made in feeding routine, dental care, and anthelmintics to correct for 
these problems.  Since PPID horses are commonly affected with laminitis, attention to good hoof 
care is essential.  Diet management and exercise can also help with decreasing the likelihood of 
development of laminitis.  By decreasing non-structural carbohydrates and increasing insulin 
sensitivity with exercise, it appears that these horses are less susceptible to laminitis.38  Infections 
incurred by PPID affected horses may need to be treated for longer periods of time with 
appropriate antibiotic therapy.   
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Pharmacologic therapy has focused on the decreased production of POMC peptides or 
decreasing the production cortisol from the adrenal cortex.  Cyproheptadine, a nonselective 5-
hydroxytryptamine receptor blocking agent (serotonin antagonist), was used initially due to the 
large effect it exerts on rat pituitary POMC peptide production.38,41 In humans, administration of 
cyproheptadine resulted in a decrease in ACTH and β-END secretion from ACTH-producing 
tumors.41  Cyproheptadine is given at 0.6 to 1.2 mg/kg orally every 24 hours, however other 
sources indicate that the appropriate dose is 0.3 to 0.5 mg/kg orally once daily.26,38  Adverse 
effects associated with  cyproheptadine administration is rare even with double dose 
administration.38   
Several clinical studies have been performed to evaluate the effect cyproheptadine on 
PPID horses.  These studies evaluated improvement of clinical signs and diagnostic test results.  
In a very small study, cyproheptadine improved clinical signs in only 1 out of 4 ponies affected 
with PPID.22  However, other studies by Couëtil and Perkins et al. found that cyproheptadine 
improved clinical signs and appeared to improve endocrine test results.8,37,39  Couëtil found that 
ACTH concentrations decreased, but rarely to normal values, while Perkins et al. found that 
ACTH concentrations did return to normal levels after treatment.8,37  Schott et al. found that 
follow up endocrinologic tests (dexamethasone suppression test, TRH stimulation test, insulin 
concentrations, and ACTH concentrations) did not show significant improvement in horses 
treated with cyproheptadine compared to untreated horses.39  Results from these some of the 
studies could be confounded by changes made in management of theses horses, since these were 
mainly field studies.     
Dopamine agonists replace the inhibitory peptide dopamine to decrease production of 
POMC peptides.  Orth et al. in 1982 found that an intravenous infusion of dopamine caused a 
significant decrease in POMC peptide concentrations.35 Utilizing the theory that replacement of 
dopamine would suppress POMC peptide production, pergolide and bromocriptine have both 
been evaluated for the treatment of PPID in horses.  Bromocriptine has been administered orally, 
intravenously, or by subcutaneous injection at a dose of 0.03 to 0.09 mg/kg every 12 hours.38,41  
It has been shown to be an effective treatment of PPID; however it is not readily available 
commercially and appears to have a low bioavailability in the horses.38  For these reasons, 
pergolide is the most common dopamine agonist used to treat PPID in horses. 
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 There are several reports describing the effects of pergolide on clinical signs and on 
endocrine tests.  Improvements in clinical signs are based on owner perceptions in most reports, 
and there are few well designed studies.    Schott et al. reported clinical signs improved in over 
80% of pergolide treated horses.39  However, after endocrine evaluation of these same horses 
only about one third of these horses were normal.39 Donaldson et al. in 2002 found that pergolide 
treated horses had a significant reduction in laminitis or laminitic episodes.10 In this same study, 
PPID horses had a significant decrease in plasma ACTH concentrations after initiation of 
pergolide treatment, in comparison to cyproheptadine treatment.10  However, there was not a 
untreated control group in this particular study.  Orth et al. in 1982 evaluated the effect of oral 
pergolide (0.01 mg/kg) on POMC peptides at 0.01mg/kg in a single horse with PPID.35  In this 
study there was a significant decline in ACTH, β-END, and α-MSH, although they did not reach 
normal levels.35  He also noted that despite a decrease in ACTH, plasma cortisol only declined 
slightly for a short period of time.35   
Pergolide is given orally with a dose range of 0.006 to 0.01 mg/kg every 24 hours.38  
Improvement in clinical signs typically takes up to 6 weeks to occur; if improvements in clinical 
signs or endocrinologic tests are not appreciated the dose of pergolide used can be slowly 
increased.  Adverse effects with pergolide treatment are rare but range from colic, anorexia, and 
diarrhea; these signs are typically associated with higher dose administration.38  The use of 
pergolide has been enhanced by the increase in price of cyproheptadine, the availability of a less 
expensive compounded product, and the scientific literature confirming the beneficial effects of 
treatment with pergolide.  Pergolide was recently pulled from human pharmacies due to 
complications with human Parkinson’s patients, thus the only way to obtain pergolide is through 
compounding pharmacies. Davis et al. in 2009 evaluated the effects of compounding and storage 
condition on the stability of compounded pergolide.9  They found that once compounded into an 
aqueous vehicle, pergolide is unstable and should be kept protected from light, refrigerated, and 
not used 30 days after compounding.9 
Drugs that inhibit adrenal steriodogenesis that have been used to treat PPID include 
trilostane, a competitive 3-β hydroxysteriod dehydrogenase, or o,p’-DDD, an adrenocorticolytic 
agent.  O,p’-DDD acts to destroy the adrenal cortex that results in decreased cortisol secretion, 
while trilostane blocks cortisol synthesis by the adrenal cortex.  Early studies reported poor 
results with the administration of o,p’-DDD.38  However, a recent study performed by McGowan 
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and Neiger found a significant improvement in clinical signs and cortisol response to TRH 
stimulation test in PPID horses treated with trilostane.32  Twenty horses in this study received 0.4 
to 1mg/kg orally once daily for 30 days without adverse effects noted.32 PPID was not confirmed 
with histopathology after treatment in these horses.  It has been proposed that possibly multiple 
drugs should be used to treat PPID in horses, possibly a combination of pergolide and trilostane.  
It would be beneficial to detect adrenal hyperplasia prior to starting trilostane therapy in these 
horses, however this multilevel approach may be what is necessary for some previous 
unresponsive horses.  It is unclear at this time if the combination of these drugs would have 
enough beneficial effects in PPID horses to warrant use, however this may be on the horizon for 
future studies.       
 
Pergolide: Pharmacokinetic-Pharmacodynamic Modeling 
Pharmacokinetics 
Pharmacokinetic parameters for pergolide have only been evaluated in humans to this 
point.  It was previously used to treat Parkinson disease and restless leg syndrome in humans 
until cardiac complications warranted it be pulled from the human market.  Pergolide is a 
dopamine agonist acting mainly at D2 and D3 dopamine receptors, see chemical structure in 
Figure 1.5.40  However, even in humans, the pharmacokinetics of pergolide have not been well 
documented, due to the small doses used, and the extensive first-pass metabolism resulting in 
very low plasma concentrations.5,20  Recent developments in the field of high-performance liquid 
chromatography (HPLC)-tandem mass spectrometry assay has allowed measurement of very low 
pergolide concentrations in plasma (lower limit of quantification:10 pg ml-1).5,19,20,40  In humans, 
pergolide is often administered at a dose of 1 mg q 8 hours (0.014 mg/kg based on a 70 kg body 
weight) for treatment of Parkinson’s disease.40  Peak plasma concentrations of the drug are 
achieved within 2-3 hours following oral administration.5,40  Pergolide has a large apparent 
volume of distribution (14,000 L) with a half-life of approximately 21 hours.5,40  The very large 
apparent volume of distribution is at least partially responsible for the low plasma 
concentrations. 
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Pharmacodynamics 
The pharmacodynamics of pergolide in relation to pharmacokinetic evaluation has only 
been performed in humans.  In human studies the evaluation of pharmacodynamics has typically 
focused on the patient’s Unified Parkinson’s Disease Rating Scale (UPDRS) motor score in 
relation to pergolide exposure.40  In a study by Thalamas et al., there was a significant 
correlation between decreased motor scores (or improved motor function) and the area under the 
plasma concentration-time curve (AUC) .40  There was a general improvement in motor function 
with increasing time to maximum concentration (Cmax), but this was not statistically significant 
.40   
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Figure 1.1: Equine Pituitary Gland 
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Figure 1.2: Pituitary POMC peptide metabolism in pars distalis 
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 Figure 1.3: Pituitary POMC peptide metabolism in pars intermedia 
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Figure 1.4: POMC pathway with pars intermedia or pars distalis/anterior processing, 
adapted from Schott et al.38 
 
 
 
Figure 1.5: Pergolide chemical structure 
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Table 1.1: Overview of number of PPID horses and ponies in current literature38 
 Heinrichs et al 
(1990)17 
Hillyer et al 
(1992)18 
Boujon et al 
(2003)6 
Van der Kolk et al 
(1993)46 
Couetil et al 
(1996)8 
Schott et al 
(2001)39 
Number of 
equids 
19 17 5 21 22 77 
Number of 
ponies 
NR  11 (65%) NR 12 (63%) 11 (50%) 15 (19%) 
Age:Mean 
(range) 
19.1 (7-31) 20.2 (12-34) 18.2 (13-24) 21 (12-30) 21.5 (8-31) 22.8 (12-34) 
Sex 11♀/6♂/2NR 6♀/11♂ 4♀/1♂ 8♀/13♂ 11♀/11♂ 37♀/40♂ 
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 Table 1.2: Overview of clinical signs (%) seen in PPID horses from current litterature38 
 Heinrichs 
et al 
(1990)17 
Hillyer et 
al (1992)18 
Boujon et 
al (1993)6 
Van der 
Kolk et al 
(1993)46 
Couetil et 
al (1996)8 
Schott et 
al (2001)39 
Hirsutism 47% 94%   100% 100%   95%    83% 
 
Hyperhidrosis NR 59% 67% NR 14% 33% 
Weight loss/ 
muscle wasting 
NR  88% NR 38% 50% 47% 
Abnormal fat 
distribution 
NR  12% 67% 19% 9% 29% 
Lethargy NR 82% NR NR 43% NR 
Chronic 
Laminitis 
NR 82% NR 24% 59% 52% 
Polyuria/ 
Polydipsia 
26% 76% 17% NR 32% 34% 
Chronic 
Infections 
32% 48% 33% NR 27% NR 
Neuro signs  21% 6% 50% 10% NR NR 
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CHAPTER 2 - Pharmacokinetics of pergolide in normal mares 
Introduction  
Pituitary pars intermedia dysfunction (PPID) is a common metabolic disease that occurs 
in geriatric horses due to dopaminergic neurodegeneration.5,6,7,9  This disease, although more 
recently understood, has been diagnosed in horses for several decades.  PPID typically occurs in 
horses over 15 years of age.  The loss of hypothalamic dopaminergic neurons, which provide 
inhibitory control of the pars intermedia, results in an increase in production of pro-
opiolipomelanocortin (POMC) peptides which include ACTH, α-MSH, β-END, and CLIP.  The 
increase in this hormone/peptide production causes the common clinical signs associated with 
PPID which include hirsutism, PU/PD, immunosuppression, and laminitis.9  PPID can result in 
significant morbidity and mortality.  Laminitis and immunosuppression often result in euthanasia 
of affected horses.   
The treatment choice for PPID is pergolide, a dopamine agonist.9  However, there are no 
pharmacokinetic data about the use of this drug in horses.  Pergolide was first used in human 
medicine for treatment of Parkinson’s disease.1,10  The recommended dose and frequency of 
administration of pergolide to horses with PPID are largely based on clinical impression.  The 
dose of pergolide used in horses ranges from 0.01 to 0.002 q 12 to 24 hours.9  Improvement in 
clinical signs, decreases in ACTH concentrations, and improvement in dexamethasone 
suppression tests are reported in horses with PPID treated with 0.002- 0.005 mg/kg of pergolide 
q 24 hours.2,9  Adverse effects associated with pergolide administration have been reported to be 
minimal in horses, in comparison to human complications. 
While the use of pergolide is a logical approach for therapy in horses with PPID the 
pharmacokinetic and pharmacodynamic (PK-PD) relationship for suppression of POMC related 
peptides have not been established in the horse.  Recent development in the field of high-
performance liquid chromatography (HPLC)-tandem mass spectrometry assay has allowed for 
measurements of very low pergolide concentrations in plasma (range of pg/ml).3,4  This has 
allowed for some recent published reports of the pharmacokinetics of pergolide in humans.  The 
first objective of this study was to provide pharmacokinetic data on the metabolism of pergolide 
in horse.  A secondary focus of our study to determine the PK-PD effect of oral pergolide 
administration on ACTH and α-MSH in normal horses.   
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Materials and Methods 
Animals- Seven healthy adult female horses were used in the study, which was approved by the 
Kansas State University Institutional Animal Care and Use Committee. The mares ages ranged 
from 3-17 years of age and breeds included 3 Quarter Horses, 3 Thoroughbreds, 1 Warmblood, 
and 1 Quarter Horse Cross.  Body weight of the mares ranged from 355-582 kg.  One horse was 
used in a pilot study to generate the initial pharmacokinetic data.  The other six horses were used 
in the main pharmacokinetic-pharmacodynamic study. Physical examinations were within 
normal limits.  There were no clinical signs of PPID, and haircoats were normal. An overnight 
dexamethasone suppression test was normal on all mares. Horses were housed in dirt paddock 
prior to the study, with prairie grass hay and water. 
 The mares were allowed free access in runs with shelter at all times other than during the 
study periods. The study was started at the end of June 2007. Rectal palpations with 
ultrasonography were performed to confirm ovulation 24-48 hours prior to enrollment in study 
period.  At that time the mares were brought into an individual stall, weighed, and an intravenous 
(iv) jugular catheter placed.  Mares remained in the individual stall for the entire study period of 
6 days.  Water, a pelleted diet, and ad libitum prairie grass hay were available at all times 
throughout the study period, except for the 8 hour fasting period prior to drug or placebo 
administration on day 1.  All mares were accustomed to handling and blood collection was 
facilitated via the preplaced jugular catheter. 
Drug Administration-  
Pilot pharmacokinetic study: A single dose of 0.01mg/kg of pergolide was administered by 
mouth following an eight hour fast.   
Pharmacokinetic-Pharmacodynamic study:  Each of the six horses received drug (0.01mg/kg 
oral pergolide in molasses) or oral molasses after an eight hour fast on day 1.  Doses were 
rounded up or down to the closest 0.5mg due to pergolide tablet formation being 1mg tablets that 
could easily be halved.  Oral medications were administered by two investigators via a dosing 
syringe. 1mg pergolide tablets were obtained from a local human pharmacy for use in this study.  
Once a dose was calculated the tablets were crushed, placed into an oral dosing syringe, and then 
mixed with molasses.   
Collection of samples and measurement of drug concentrations-  
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Pilot Pharmacokinetic Study: A single horse was brought into a stall the night before the study.  
An iv jugular catheter was placed.  Blood samples were collected via a 14-guage, 5.25-inch 
polyurethane catheter inserted into the right or left jugular vein, which was placed on day -1.  An 
area over the jugular vein was clipped, aseptically prepared with chlorhexidine gluconate 4%, 
and rinsed with 70% isopropyl alcohol prior to infiltration of the skin with 2% lidocaine HCl in 
preparation for catheter placement.  Jugular catheters were monitored for any signs of 
inflammation, if these signs did occur the catheter was removed and then replaced in the other 
jugular vein.  The horse was administered 0.01mg/kg of pergolide by mouth following an eight 
hour fast.  Blood to determine for pergolide concentrations was collected at 0.25, 0.5, 1, 1.5, 2, 
2.5, 3, 4, 5, 7, 11, 16, 24, 36, 48, 60, 72, 84, and 120 hours in sodium heparin blood tubes. Blood 
samples were immediately placed on ice.  Plasma was separated from red blood cells via 
refrigerated centrifuge. Plasma was stored in appropriately labeled polypropylene tubes at -70°C 
until analysis.  
Pharmacokinetic-Pharmacodynamic study: In a randomized, blinded, cross-over design, six 
mares were either treated with pergolide or placebo.  Horses were numbered from 1 to 6.  Even 
numbered horses received pergolide in the first trial, and odd numbered horses received 
pergolide in the second trial.  The collection of blood samples were performed by technicians 
unaware of what the horses had been treated with (pergolide or placebo).   Horses were brought 
into an individual stall in the evening (day -1), and an iv jugular catheter was placed. Mares 
remained in their stalls for the entire study period (days -1, 0, 1, 2, 3, 4).  There was a fourteen 
day washout period between either trial (placebo or pergolide).   
Blood was collected from days 0 to 4, every 4 hours for ACTH and every 12 hours for α-
MSH concentrations.  Pergolide or placebo was administered on day 1 at 8:00 AM.  Blood was 
also collected for pergolide, ACTH, and MSH concentrations at 0, 0.1, 0.25, 0.33, 0.5, 0.75, 1, 
1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, and 96 hours after administration of pergolide or placebo. The 
time of blood collected for pergolide analysis was determined based on the data generated from 
the horse in the pilot pharmacokinetic study. Blood was collected in the same manner for control 
or treatment periods, and the amount of blood collected varied based the number of samples 
needed per sampling time.  Blood was collected into EDTA tubes for hormone analysis and 
sodium heparin tubes for pergolide analysis.  Blood samples were immediately placed on ice.  
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Plasma was separated from red blood cells within 30 minutes of collection via a refrigerated 
centrifuge.  Plasma was placed into polypropylene tubes at -70°C for analysis. 
Pergolide analysis:  The analytical method for extraction of pergolide from plasma samples was 
a solid phase extraction method.  It began by thawing the plasma then treatment with twice the 
volume of cold acetonitrile in order to precipitate proteins.  0.45 micron ultracentrifugation filter 
units were used to filter the sample into the desired analytical sample.  Then 5-20 microliters 
(varied based on the expected pergolide concentration) were injected into the UPLC-MS/MS.  
Separation of the analyte occurred on an Xterra MS C18, 5 micrometer, 2.1 x 150 mm column or 
equivalent with a mobile phase of acetonitrile/ammonium acetate (60:40, v/v) with a flow rate of 
0.3mL/min. Once separation had occurred 10 microliters were injected into the UPLC/MS/MS.  
The lower limit of quantification was 0.5 ng/mL with a 10:1 noise to peak ratio.  A correlation 
coefficient of 0.995 to known standards was obtained. 
Hormone analysis: Plasma α-MSH concentrations were analyzed using a commercially 
available human radioimmunoassay, validated for use in horses, in duplicate.  Assay sensitivity 
for α-MSH ranged from 2.17-2.62 pMol/L, intra-assay coefficient of variance ranged from 1.5-
8.2%, and the inter-assay coefficient of variance was 7.81%.  Plasma ACTH concentrations were 
analyzed in duplicate using a chemiluminescent enzyme immunoassay with a limit of 
quantification of 12 -1200pg/ml.   
Statistical Analysis- Pharmacodynamic parameters (ACTH and α-MSH) were performed for 
treatment and control.  Both hormones were evaluated using a multiple ANOVA for repeated 
measures comparing treatment, time, and period.  This analysis was performed using JMP IN 
5.1® (SAS Institute, Cary, NC) with statistical significance achieved when p<0.05.   
Pharmacokinetic analysis-- Once pergolide concentration verses time was determined for each 
mare, the data was entered into a commercially available program for non-compartmental 
pharmacokinetic analysis (WinNonLin® (Pharsight Corporation, Cary, NC)).  The following 
pharmacokinetic parameters were calculated: AUC0-last, elimination rate constant (kel), terminal 
half-life (t½el), total body clearance (corrected for unknown bioavailability) (CLB/F), apparent 
volume of distribution (also corrected for unknown bioavailability) (Vd/F), maximal 
concentration (Cmax), time to maximal concentration (Tmax) and mean residence time.  AUC0-last 
was calculated using the linear trapezoidal rule and extrapolated to infinity by adding Clast/kel.  
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Kel is the slope of the terminal portion of the time-concentration curve and the t½el was calculated 
as 0.693/kel. Vd/F and CLB/F were calculated using standard equations.  
 Pharmacodynamic analysis- ACTH measurements and α-MSH measurements were evaluated 
using a multiple analysis of variance for repeated measures comparing treatment, time, and 
period.   Analysis was performed using the commercially available software program JMP IN 
5.1® (SAS Institute, Cary, NC). Statistical significance was considered with a p-value less than 
0.05.  
Results  
Oral pergolide was tolerated well by 5 of the mares.  One mare developed mild 
depression and anemia.  The depression started at hour 3 after administration and continued until 
hour 32.   
 The pergolide concentrations for each horse at each time interval after oral administration 
are shown in table 2.1 and plotted in figure 2.1, 2.2, 2.3, 2.4, 2,5, and 2.6.  The concentrations 
were below the level of quantification (LOQ=0.5ng/ml) at times 0, 24, and 48 for all horses.  
Estimates of the pharmacokinetic parameters using a noncompartmental analysis for each horse 
with mean and standard deviation are shown in table 2.2.  The mean half life of oral pergolide in 
this study was 5.86 hours (SD=3.42 hours).  The mean maximum concentration was 4.05 ng/ml 
(SD=2.02 ng/ml) with the median time to maximum concentration being 0.415 hours (Range: 
0.33-1 hour).  The mean AUC0-∞ was 14.08 h*ng/ml (SD= 7.46 h*ng/ml).  The calculated 
apparent volume of distribution corrected for unknown bioavailability was 3,000 ml/kg 
(SD=1,354 ml/kg).  The calculated apparent clearance corrected for unknown bioavailability was 
1,204 ml/kg/hr (SD=722 ml/kg/hr).  Bioavailability could not be calculated due to the lack of an 
available IV formulation for comparison.  During the analysis of pergolide concentrations it was 
noted that there were two peaks during the absorption phase most likely attributable to biphasic 
absorption. 
 Mean ACTH concentrations for pergolide and placebo administrations are plotted in 
figure 2.7.  Based on analysis there was no statistically significant difference found between 
treatment, time, or period in reference to ACTH concentrations.  Mean α-MSH concentrations 
for placebo and control are plotted in figure 2.8.  Analysis revealed a statistically significant 
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treatment by period interaction (p<0.02).  When evaluated separately the p-value for effect of 
period was 0.06 and the p-value for effect of treatment was 0.77.      
 
Figures and Tables 
Time 
(hrs) 
ID 
0 0.1 0.25 0.33 0.5 0.75 1 1.5 2 3 4 5 6 8 12 24 48 
1 <LOQ 0.94 3.13 4.83 3.45 2.95 4.15 1.44 1.49 1.22 1.0 0.81 0.73 0.59 <LOQ <LOQ <LOQ
2 <LOQ 0.51 0.76 0.96 1.3 0.95 2.11 0.93 0.91 0.66 0.61 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
3 <LOQ 0.63 1.76 2.52 2.46 1.78 2.07 1.59 1.12 0.91 0.72 0.57 <LOQ 0.53 <LOQ <LOQ <LOQ
4 <LOQ 1.70 4.43 6.04 5.17 6.20 4.48 2.88 1.49 1.54 0.98 0.90 0.74 0.77 0.60 <LOQ <LOQ
5 <LOQ <LOQ 1.51 2.17 2.22 1.96 2.18 0.76 0.68 0.62 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
6 <LOQ 1.45 2.91 6.42 5.67 5.65 4.13 2.29 1.85 1.20 1.14 0.89 0.68 0.55 <LOQ <LOQ <LOQ
 
Table 2.1: Pergolide concentration for each horse at sample time 
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  Kel        
(h-1) 
 T1/2 
(h) 
Cmaz 
(ng/ml) 
AUC 0-last 
(h*ng/ml) 
AUC0-∞ 
(h*ng/ml) 
AUC % 
Extrapolated 
MRT 
(h) 
Tmax (h) Apparent 
Vd/F 
(ml/kg) 
Apparent 
Cl/F 
(ml/kg/hr)
Horse 
1 
0.11 6.33 4.83 10.66 16.01 33.41 7.54 0.33 2432.72 781.64 
Horse 
2 
0.19 3.65 2.11 3.69 6.90 46.58 5.25 1 5047.96 1921.36 
Horse 
3 
0.22 3.10 2.52 7.53 9.89 23.83 5.20 0.33 4208.09 1080.26 
Horse 
4 
0.06 12.39 6.20 16.40 27.16 39.62 14.07 0.75 1835.24 507.15 
Horse 
5 
0.12 5.59 2.22 3.49 8.53 59.06 7.02 0.5 3301.73 2265.81 
Horse 
6 
0.17 4.07 6.42 12.77 15.97 20.04 4.72 0.33 1663.27 669.64 
Mean 0.15 5.86 4.05 9.09 14.08 37.09 7.30 0.415 
(Median) 
3,082 1,204 
SD 0.06 3.42 2.02 5.15 7.46 14.56 3.50 0.33-1 
(Range) 
1,663-
5,048 
(Range) 
507-2,269 
(Range) 
 
Table 2.2: Pharmacokinetic parameters for non-compartmental model for oral pergolide 
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Figure 2.1: Pergolide concentration in Animal 1 verses time 
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Figure 2.2: Pergolide concentration in Animal 2 verses time 
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Figure 2.3: Pergolide concentration in Animal 3 verses time 
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Figure 2.4: Pergolide concentrations in Animal 4 verses time 
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Figure 2.5: Pergolide concentrations in Animal 5 verses time 
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Figure 2.6: Pergolide concentrations of Animal 6 verses time 
 
 
 
 
Figure 2.7: ACTH concentrations after pergolide or placebo administration 
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Figure 2.8: MSH concentrations for pergolide and placebo treated horses 
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 Discussion  
     Pergolide has been used for many years to treat PPID in geriatric horses.  There are 
several case series about the use of pergolide in affected horses; however none of these studies 
have actually evaluated the pharmacokinetics (or the PK-PD effects) of pergolide in horses. Our 
study documents that horses absorb pergolide when administered orally, and also provides some 
initial pharmacokinetic data.   
The pharmacokinetic parameters obtained from non-compartmental analysis in our study 
indicate that horses absorb and clear pergolide much more efficiently than humans.  The T1/2 in 
our study was a mean of 5.86 hours; this is much shorter than the 21 hours found by Thalamas et 
al. in human patients.10   The time to maximum concentration in horses was also much shorter 
compared to humans, 0.415 hours compared to 2-3 hours.  This may indicate that the interval 
between administrations may need to be shortened due to a shorter half life than expected.  
Bioavailability could not be determined due to the lack of an intravenous administration for 
comparison.  The analytical method in our study had a higher lower level of quantification (0.5 
ng/ml) than in the human studies (0.01 ng/ml).10  This higher level of quantification may have 
resulted in an under-estimation of the half-life due to missing of the slower terminal phase of 
elimination.  The poor lower limit of quantification may be due to a difference in protein or lipid 
concentration in human verses horse plasma, an overly aggressive extraction method, or a lack of 
stability in frozen plasma.  Performing the study at steady state and performing a different 
analytical method may help improve the lower limit of quantification if the experiment is 
performed again. 
The pergolide dose used in this study was 0.01 mg/kg PO, which is much higher than the 
doses used clinically (range of 0.002 to 0.005 mg/kg).   This study was a pilot project and the 
main objective was to determine the pharmacokinetics and PK-PD model of the suppressive 
effects of pergolide on POMC peptides.  We chose a dose of 0.01 mg/kg based on the work 
performed by Orth et al. in 1982.8   This study reported that a single dose of pergolide (at 0.01 
mg/kg) to a single horse resulted in a decrease in POMC peptide concentrations for 48 hours.8  In  
our study, this was not observed; however the Orth et al. study used a horse with PPID (thus 
having much higher POMC peptide concentrations).8  The higher dose was well tolerated by all 
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horses except one that became mildly depressed and anemic 3 hours after administration but was 
normal by hour 32.  Pergolide administered at a range of 0.002 to 0.005 mg/kg q 24 hrs resulted 
in improved clinical signs and a decrease in ACTH concentrations.2  Schott et al. reported that 7 
out of 20 horses developed a normal dexamethasone suppression test when treated with 
pergolide at 0.002 mg/kg q 24 hours for 6 to 12 months.9   
We were unable to document a PK-PD relationship on the suppressive effects of 
pergolide on POMC peptide concentrations.  A statistical significant difference was not evident 
with ACTH concentrations.  However, there was a significant treatment to period (or season) 
effect noted with α-MSH analysis (p<0.02).  When evaluating the effect of period (p=0.06) and 
treatment (p=0.77) separately, it is highly suggestive that the significance is more associated with 
the effect of period rather than treatment.   We chose to conduct this study during the summer, 
when α-MSH concentrations would be moderately increased.  Concentrations of α-MSH during 
the spring and winter in normal horses are close to the lower limits of sensitivity.  Thus we were 
concerned that it might be difficult to measure the suppressive effects of pergolide during this 
time.  Our particular study design (cross over design), with a14 day wash-out period between 
trials, resulted in an increase in α-MSH concentrations during the second trial.  An alternative 
would be to conduct each trial with a different set of horses, however this would likely result in 
increase variability and therefore the number animals needed to show significant differences. 
The correct dose and frequency of administration of pergolide for treatment of PPID in 
horses is currently unknown, and our current study does not answer these questions.  Further PK-
PD studies on the suppressive effects of pergolide on POMC peptide concentrations should be 
performed to determine the most appropriate dose and dosing interval for treating PPID in 
horses.  Ways to improve this study or improve the likelihood of obtaining better PK-PD 
information would include performing the study at a steady state, performing the study in a 
larger number of animals, performing the study when there is less effect of season on POMC 
peptide production, and performing the study in PPID affected horses.  Horses with PPID have 
higher levels of POMC peptides and may have less variation due to season, this would allow for 
better evaluation of pergolide’s effect on these peptides.  Other than changing the season of the 
study, to execute these changes would increase the cost of the study significantly and finding a 
large number of PPID affected horses can be difficult at times. 
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